The aim of this study was to examine continuation of subcutaneous and intramuscular depot medroxyprogesterone acetate (DMPA-SC and DMPA-IM) when administered by Village Health Teams (VHTs) in Uganda.
Participants were family planning clients of VHTs who had decided to initiate injectable use. Women selected DMPA-SC or DMPA-IM and study staff followed them for up to four injections (providing 12-months of pregnancy protection) to determine contraceptive continuation. Study staff interviewed women at their first injection (baseline), second injection, fourth injection, and if they discontinued either product. Information from all interviews are included in this dataset. The methods and results for this study are described in the linked publication